Janus kinase inhibitors for the treatment of atopic dermatitis-evaluation of current data and practical experience

Background Atopic dermatitis is a common chronic inflammatory skin disease and has a major impact on patient's quality of life. Janus kinase inhibitors were recently approved for the treatment of atopic dermatitis. Objectives To summarize current data on efficacy and safety of Janus kinase inhibitors for the treatment of atopic dermatitis as well as guidelines for the use in clinical practice. Materials and methods Summary and assessment of currently available data. Results Three Janus kinase inhibitors are approved for the treatment of moderate to severe atopic dermatitis: baricitinib, upadacitinib and abrocitinib. Clinical trials and first real-life data demonstrate rapid and strong reduction of pruritus and clinical signs of atopic dermatitis as well as improvement of patient's quality of life. The safety profile is favorable, although data on long-term safety especially for the treatment of atopic dermatitis patients are still lacking. Conclusions Janus kinase inhibitors enrich the therapeutic portfolio for the treatment of atopic dermatitis. When carefully taking into consideration contraindications, side effects, and necessary laboratory controls, they represent a highly effective and safe treatment option for affected patients.

Automated summary

Janus kinase inhibitors are effective and safe treatment options for atopic dermatitis, providing rapid relief of pruritus and improvement in patients' quality of life.